Conduit Pharmaceuticals (CDT) Stock Price, News & Analysis

Company Overview

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Key Stats

• Today's Range: $0.51 to $0.63
• 50-Day Range: $0.59 to $2.85
• 52-Week Range: $0.55 to $350.00
• Volume: 388,701 shs
• Average Volume: 1.07 million shs
• Market Capitalization: $4.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Conduit Pharmaceuticals Stock Analysis - MarketRank™

Conduit Pharmaceuticals scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Conduit Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Conduit Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Conduit Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

105.83% of the float of Conduit Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Conduit Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Conduit Pharmaceuticals has recently increased by 66.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Conduit Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Conduit Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

105.83% of the float of Conduit Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Conduit Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Conduit Pharmaceuticals has recently increased by 66.57%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.23

News Sentiment

Conduit Pharmaceuticals has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Conduit Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 7 people have searched for CDT on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

MarketBeat Follows

4 people have added Conduit Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Conduit Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.93% of the stock of Conduit Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 3.29% of the stock of Conduit Pharmaceuticals is held by institutions.

CDT Stock Analysis - Frequently Asked Questions

How have CDT shares performed this year?

Conduit Pharmaceuticals' stock was trading at $6.86 on January 1st, 2025. Since then, CDT stock has decreased by 91.0% and is now trading at $0.62.
View the best growth stocks for 2025 here.

How were Conduit Pharmaceuticals' earnings last quarter?

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) issued its quarterly earnings data on Friday, March, 28th. The company reported ($20.33) earnings per share for the quarter.

When did Conduit Pharmaceuticals' stock split?

Conduit Pharmaceuticals's stock reverse split before market open on Monday, January 27th 2025. The 1-100 reverse split was announced on Thursday, January 23rd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Conduit Pharmaceuticals?

Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Conduit Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Conduit Pharmaceuticals investors own include BIOLASE (BIOL), Daré Bioscience (DARE), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Cara Therapeutics (CARA), Canoo (GOEV) and Jiuzi (JZXN).

Company Calendar

• Last Earnings: 3/28/2025
• Today: 4/09/2025
• Next Earnings (Estimated): 4/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CDT
• Previous Symbol: NASDAQ:CDT
• CIK: 1896212
• Web: www.conduitpharma.com
• Phone: 760-471-8536
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($39.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-540,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -328.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.12
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.62) per share
• Price / Book: -0.91

Miscellaneous

• Outstanding Shares: 6,663,000
• Free Float: 710,000
• Market Cap: $3.78 million
• Optionable: Not Optionable
• Beta: 2.37